Publications by authors named "David J FitzGerald"

Claim this Profile
I
Immunization with peptide encapsulated within synthetic spores activates T cell responses and reduces tumor growth.
Domenico D'Atri, Elena Tondini, Federico Machinandiarena, Minsuk Kong, Alilin Mia, David J Fitzgerald

mBio· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunization with peptide encapsulated within synthetic spores activates T cell responses and reduces tumor growth.
Domenico D'Atri, Elena Tondini, Federico Machinandiarena, Minsuk Kong, Alilin Mia, David J Fitzgerald

bioRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-specific cargo delivery using synthetic bacterial spores.
Minsuk Kong, Domenico D'Atri, Maria Teresa Bilotta, Bailey Johnson, Taylor B Updegrove, David J Fitzgerald

Cell Rep· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing the TME to improve the efficacy of cancer therapy.
Maria Teresa Bilotta, Antonella Antignani, David J Fitzgerald

Front Immunol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Receptors on Cancer Cells with Protein Toxins.
Antonella Antignani, Eric Chun Hei Ho, Maria Teresa Bilotta, Rong Qiu, Robert Sarnvosky, David J FitzGerald

Biomolecules· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analgesia by Deletion of Spinal Neurokinin 1 Receptor Expressing Neurons Using a Bioengineered Substance P-Pseudomonas Exotoxin Conjugate.
Michael J Iadarola, Matthew R Sapio, Xunde Wang, Hector Carrero, Maria Luisa Virata-Theimer, David J FitzGerald

Mol Pain· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
Robert J Kreitman, Martin S Tallman, Tadeusz Robak, Steven Coutre, Wyndham H Wilson, David J FitzGerald

Blood· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.
Antonella Antignani, Lesley Mathews Griner, Rajarshi Guha, Nathan Simon, Matteo Pasetto, David J FitzGerald

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
Fatima Ali-Rahmani, David J FitzGerald, Scott Martin, Paresma Patel, Marco Prunotto

Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity.
Matteo Pasetto, Antonella Antignani, Pinar Ormanoglu, Eugen Buehler, Rajarshi Guha, David J FitzGerald

Proc Natl Acad Sci U S A· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.
Masanori Onda, Kamran Ghoreschi, Scott Steward-Tharp, Craig Thomas, John J O'Shea, David J FitzGerald

J Immunol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted diphtheria toxin to treat BPDCN.
David J FitzGerald

Blood· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including pseudomonas exotoxin.
Antonella Antignani, Robert Sarnovsky, David J FitzGerald

Mol Cancer Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotoxins for leukemia.
Alan S Wayne, David J Fitzgerald, Robert J Kreitman, Ira Pastan

Blood· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Xiu-Fen Liu, Laiman Xiang, David J FitzGerald, Ira Pastan

Mol Cancer Ther· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.
Kevin Hollevoet, Antonella Antignani, David J Fitzgerald, Ira Pastan

J Immunother· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.
Xiu Fen Liu, David J FitzGerald, Ira Pastan

Cancer Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.
Abid R Mattoo, David J FitzGerald

Int J Cancer· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Waleed Haso, Daniel W Lee, Nirali N Shah, Maryalice Stetler-Stevenson, Constance M Yuan, David J FitzGerald

Blood· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Robert J Kreitman, Martin S Tallman, Tadeusz Robak, Steven Coutre, Wyndham H Wilson, David J Fitzgerald

J Clin Oncol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
Hui Wei, Laiman Xiang, Alan S Wayne, Oleg Chertov, David J FitzGerald

Proc Natl Acad Sci U S A· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
David J FitzGerald, Alan S Wayne, Robert J Kreitman, Ira Pastan

Cancer Res· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
David J Fitzgerald, Elizabeth Moskatel, Gal Ben-Josef, Roberta Traini, Tara Tendler

Leuk Lymphoma· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Robert J Kreitman, Evgeny Arons, Maryalice Stetler-Stevenson, David J P Fitzgerald, Wyndham H Wilson

Leuk Lymphoma· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aeromedical decision making in attention-deficit/hyperactivity disorder.
David J P Fitzgerald, Pooshan D Navathe, A Michael Drane

Aviat Space Environ Med· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis